Uveitis events during adalimumab, etanercept, and methotrexate therapy in juvenile idiopathic arthritis: Data from the biologics in pediatric rheumatology registry

Arthritis Care and Research

Volumn 67, Issue 11, 2015, Pages 1529-1535

  Foeldvari, Ivan ^a   Becker, Ingrid ^b   Horneff, Gerd ^c  

^a Hamburger Zentrum fur Kinder und Jugendrheumatologie   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c Centre for Pediatric Rheumatology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; ETANERCEPT; METHOTREXATE; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MONOTHERAPY; RECURRENT DISEASE; REGISTER; UNIVARIATE ANALYSIS; UVEITIS; ADOLESCENT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, JUVENILE; CHEMICALLY INDUCED; DRUG COMBINATION; PROCEDURES; RHEUMATOLOGY; STATISTICS;

ADALIMUMAB; ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BIOLOGICAL PRODUCTS; CHILD; COHORT STUDIES; DRUG THERAPY, COMBINATION; ETANERCEPT; FEMALE; HUMANS; MALE; METHOTREXATE; REGISTRIES; RHEUMATOLOGY; STATISTICS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84945370771     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22613     Document Type: Article

References (32)

1. Gowdie PJ, Tse SM., Juvenile idiopathic arthritis. Pediatr Clin North Am 2012; 59: 301-27.
2. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al., International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
3. Heiligenhaus A, Heinz C, Edelsten C, Kotaniemi K, Minden K., Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm 2013; 21: 180-91.
4. Chylack LT Jr, Bienfang DC, Bellows AR, Stillman JS., Ocular manifestations of juvenile rheumatoid arthritis. Am J Ophthalmol 1975; 79: 1026-33.
5. Kanski JJ., Uveitis in juvenile chronic arthritis: incidence, clinical features and prognosis. Eye 1988;Pt 6: 641-5.
6. Cabral DA, Petty RE, Malleson PN, Ensworth S, McCormick AQ, Schroeder M., Visual prognosis in children with chronic anterior uveitis and arthritis. J Rheumatol 1994; 21: 2370-5.
7. Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K., Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 2007; 46: 1015-9.
8. Vidqvist KL, Malin M, Varjolahti-Lehtinen T, Korpela MM., Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies. Rheumatology (Oxford) 2013; 52: 1999-2003.
9. Bolt IB, Cannizzaro E, Seger R, Saurenmann RK., Risk factors and long term outcome of juvenile idiopathic arthritis-associated uveitis in Switzerland. J Rheumatol 2008; 35: 703-6.
10. Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, et al., Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum 2007; 56: 647-57.
11. Angeles-Han ST, Pelajo CF, Vogler LB, Rouster-Stevens K, Kennedy C, Ponder L, et al., Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol 2013; 40: 2088-96.
12. Cole TS, Frankovich J, Iyer S, Lependu P, Bauer-Mehren A, Shah NH., Profiling risk factors for chronic uveitis in juvenile idiopathic arthritis: a new model for EHR-based research. Pediatr Rheumatol Online J 2013; 11: 45.
13. Watanabe Duffy KN, Lee J, Guzman J, Barrowman N, Morishita K, Spiegel LR, et al., A13: the research in arthritis in Canadian Children Emphasizing Outcomes (ReACCh Out) Cohort. Prospective determination of the incidence of new onset uveitis in juvenile idiopathic arthritis [abstract]. Arthritis Rheumatol 2014; 66 Suppl 11: S21-2.
14. Heiligenhaus A, Michels H, Schumacher C, Kopp I, Neudorf U, Niehues T, et al., Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int 2012; 32: 1121-33.
15. Simonini G, Paudyal P, Jones GT, Cimaz R, Macfarlane GJ., Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford) 2013; 52: 825-31.
16. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al., Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009; 68: 519-25.
17. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al., The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1638-44.
18. Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G., Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol 2014; 66: 2580-9.
19. Foeldvari I, Wierk A., Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005; 32: 362-5.
20. Heiligenhaus A, Mingels A, Heinz C, Ganser G., Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 2007; 17: 743-8.
21. Kalinina Ayuso V, van de Winkel EL, Rothova A, de Boer JH., Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol 2011; 151: 217-22.
22. Cordero-Coma M, Yilmaz T, Onal S., Systematic review of anti-tumor necrosis factor-α therapy for treatment of immune-mediated uveitis. Ocul Immunol Inflamm 2013; 21: 12-20.
23. Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, et al., A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005; 53: 18-23.
24. Simonini G, Taddio A, Cattalini M, Caputo R, De Libero C, Naviglio S, et al., Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 2011; 63: 612-8.
25. Rudwaleit M, Rodevand E, Holck P, Vanhoof J, Kron M, Kary S, et al., Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009; 68: 696-701.
26. Kotaniemi K, Saila H, Kautiainen H., Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 2011; 5: 1425-9.
27. Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT., Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res (Hoboken) 2014; 66: 1073-84.
28. Van Denderen JC, Visman IM, Nurmohamed MT, Suttorp-Schulten MS, van der Horst-Bruinsma IE., Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. J Rheumatol 2014; 41: 1843-8.
29. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al., Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810-20.
30. Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H., The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014; 53: 213-22.
31. Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED., Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNF α agents. J Pediatr 2006; 149: 833-6.
32. Ramanan AV, Dick AD, Benton D, Compeyrot-Lacassagne S, Dawoud D, Hardwick B, et al., A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials 2014; 15: 14.